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OBJECTIVE—Prolonged exposure of pancreatic -cells to si-
multaneously elevated levels of fatty acids and glucose (glucoli-
potoxicity) impairs insulin gene transcription. However, the
intracellular signaling pathways mediating these effects are
mostly unknown. This study aimed to ascertain the role of
extracellular-regulated kinases (ERKs)1/2, protein kinase B
(PKB), and Per-Arnt-Sim kinase (PASK) in palmitate inhibition of
insulin gene expression in pancreatic -cells.
RESEARCH DESIGN AND METHODS—MIN6 cells and iso-
lated rat islets were cultured in the presence of elevated glucose,
with or without palmitate or ceramide. ERK1/2 phosphorylation,
PKB phosphorylation, and PASK expression were examined by
immunoblotting and real-time PCR. The role of these kinases in
insulin gene expression was assessed using pharmacological and
molecular approaches.
RESULTS—Exposure of MIN6 cells and islets to elevated glu-
cose induced ERK1/2 and PKB phosphorylation, which was
further enhanced by palmitate. Inhibition of ERK1/2, but not of
PKB, partially prevented the inhibition of insulin gene expression
in the presence of palmitate or ceramide. Glucose-induced
expression of PASK mRNA and protein levels was reduced in the
presence of palmitate. Overexpression of wild-type PASK in-
creased insulin and pancreatic duodenal homeobox-1 gene ex-
pression in MIN6 cells and rat islets incubated with glucose and
palmitate, whereas overexpression of a kinase-dead PASK mu-
tant in rat islets decreased expression of insulin and pancreatic
duodenal homeobox-1 and increased C/EBP expression.
CONCLUSIONS—Both the PASK and ERK1/2 signaling path-
ways mediate palmitate inhibition of insulin gene expression.
These ﬁndings identify PASK as a novel mediator of glucolipo-
toxicity on the insulin gene in pancreatic -cells. Diabetes 58:
2048–2058, 2009
T
he glucolipotoxicity hypothesis posits that ab-
normalities in lipid metabolism, in conjunction
with chronic hyperglycemia, contribute to the
deterioration of -cell function in type 2 diabetes
(1,2). In vitro, prolonged exposure of isolated islets and
insulin-secreting cells to simultaneously elevated levels of
fatty acids and glucose leads to inhibition of glucose-
induced insulin secretion, impairment of preproinsulin
gene (hereafter referred to as “insulin gene”) expression,
and cell death by apoptosis (rev. in 1). Our observation (3)
that inhibition of insulin gene expression also occurs in
islets from rats chronically infused with glucose and
intralipid conﬁrmed the relevance of this phenomenon to
in vivo situations.
Studies in our laboratory have attempted to deﬁne the
cellular and molecular mechanisms of fatty acid inhibition
of the insulin gene. First, we showed that the mechanisms
by which fatty acids impair insulin secretion and insulin
gene expression are distinct (4,5). Thus, both saturated
(e.g., palmitate) and unsaturated (e.g., oleate) long-chain
fatty acids inhibit glucose-induced insulin secretion (5),
whereas only palmitate impairs insulin gene expression
(4). This is because inhibition of insulin gene expression is
mediated by de novo synthesis of ceramide, for which only
palmitate can serve as a substrate (4). Second, palmitate
inhibits glucose-induced insulin promoter activity (4)
through decreased glucose-induced MafA expression and
nuclear exclusion of pancreas-duodenum homeobox-1
(PDX-1), thereby reducing the binding activities of both
transcription factors (6).
Signaling pathways implicated in palmitate inhibition of
insulin gene expression are mostly unknown. Several
members of the mitogen-activated protein kinase family
are activated by phosphorylation in response to glucose.
Upon activation, the extracellular-regulated kinases
(ERK)1/2 promote nuclear translocation and/or binding of
PDX-1, MafA, and 2/NeuroD1 to the insulin promoter,
and in turn, these transcription factors synergistically
activate insulin gene transcription (7–11). On the other
hand, glucose activates the phosphatidylinositol-3 kinase
(PI3K)-dependent insulin signaling pathway and increases
protein kinase B (PKB) phosphorylation in -cells (12),
although the role of the PI3K pathway in the regulation of
insulin gene expression remains controversial (10,13,14).
Finally, induction of mRNA and protein expression of the
Per-Arnt-Sim kinase (PASK) in MIN6 cells and isolated
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(15).
The aims of this study were 1) to examine the effects of
glucose and palmitate on the phosphorylation state and
expression levels of ERK1/2, PKB, and PASK in MIN6
insulin-secreting cells and isolated rat islets; and 2)t o
ascertain, using pharmacological and molecular tools,
whether these signaling pathways mediate palmitate inhi-
bition of insulin gene expression.
RESEARCH DESIGN AND METHODS
Reagents and solutions. RPMI-1640 and FBS were from Invitrogen (Burl-
ington, ON). Dulbecco’s modiﬁed Eagles’s medium (DMEM) was from Wisent
(Saint Bruno, QC) and bovine growth serum was from HyClone (Logan, UT).
Fatty acid–free BSA was from Equitech-Bio (Kerrville, TX). LY 294002,
PD98059, U0126, and thapsigargin were from Calbiochem (EMD Biosciences,
San Diego, CA). Propidium iodide was from Invitrogen. C2-ceramide was from
Biomol (Plymouth Meeting, PA). Palmitate (sodium salt) and all other
reagents (analytical grade) were from Sigma (St. Louis, MO) unless otherwise
noted. Rabbit anti-PKB, anti–phospho-Ser
473-PKB, anti–phospho-p44/p42 MAP
kinase (Thr
202/Tyr
204), and anti–cleaved caspase 3 antibodies were from Cell
Signaling (New England Biolabs, Beverly, MA). Rabbit anti-ERK1/2 antibody
was from Promega (Madison, WI). Interleukin (IL)-1 was from Cedarlane
Laboratories (Burlington, ON). Rabbit anti–p85 subunit of PI3K and anti–
PDX-1 antibodies were from Upstate Biotechnology (Lake Placid, NY). Rabbit
anti-hPASK (U2501), anti-m/rPASK (U2508) antibodies, and hPASK adenovi-
ruses were generated as described (16). Insulin radioimmunoassay kits were
from Linco Research (St. Charles, MI). Palmitate and C2-ceramide solutions
were prepared as described (4). The ﬁnal molar ratio of palmitate:BSA was
5:1. All control conditions included a solution of vehicle (ethanol:H2O) mixed
with fatty acid–free BSA.
Male Wistar rats (225–275 g) (Charles River Laboratories, Wilmington, MA)
were housed on a 12-h light/dark cycle with free access to standard laboratory
rat diet and water. All procedures were approved by the Institutional
Committee for the Protection of Animals at the Centre Hospitalier de
l’Universite ´ de Montre ´al.
Rat islet isolation and cell culture. Rat islets were isolated as described
(4,17). Isolated islets were precultured for 16 h at 2.8 mmol/l and then exposed
to 2.8 or 16.7 mmol/l glucose in various experimental conditions as described
in RESULTS. MIN6 cells (passage 28–40) were maintained as previously
described (18). Cells were seeded in six-well plates at a density of 1  10
6 cells
per well for 3–5 days. One day before the experiment, cells were cultured in
medium containing 5.5 mmol/l glucose for 16 h. Cells were serum-starved in
medium containing 0.5% BSA for 2 h and then exposed to various experimen-
tal conditions as described in RESULTS.
Acridine orange and propidium iodide ﬂuorescent staining. Islets were
incubated for 30 min with 1 mol/l acridine orange and 15 mol/l propidium
iodide. Stained islets were examined under a Leica TCS SP5 confocal
microscope (Leica Microsystems [Canada], Richmond Hill, ON). Living cells
were identiﬁed by green staining (Acridine orange) and dead cells by
brown-red staining (propidium iodide). For immunohistochemistry, MIN6
cells were ﬁxed with 3.7% formaldehyde for 30 min and permeabilized in cold
methanol for 20 min. After saturation with 5% normal horse serum, cells were
incubated with rabbit anti–PDX-1 antibody, followed by ﬂuorescein isothio-
cyanate goat anti-rabbit (Vector, Burlingame, CA). Cells were observed under
a ﬂuorescent microscope (Leica Microsystems, Bannockburn, IL).
Adenoviral infection of islets and MIN6 cells. The appropriate titer of
recombinant adenovirus (Adv) encoding luciferase (Adv-Luc) or human PASK
(Adv-hPASK [16]) was determined in pilot experiments. MIN6 cells were
subcultured in six-well plates (1  10
6 cells per well). After 3 days of culture
to reach 60% conﬂuence, MIN6 cells were infected with 4  10
5 plaque-
forming unit/cell of Adv-Luc or Adv-hPASK for 2 h, after which the medium
was replaced and the cells further cultured for 16 h before serum starvation
and exposure to various experimental conditions as described in RESULTS. For
arterial delivery of adenoviral vectors in rat pancreas, Wistar rats were
anesthetized and subjected to laparotomy. After ligation of the portal vein, the
superior aorta, and the hepatic, mesenteric, and right and left renal arteries,
adenoviruses (4.10
10 pfu/pancreas) were injected in the celiac trunk of the
inferior aorta as described (19).
Protein extraction and immunoblotting. Proteins from cells or islets were
extracted and resolved by SDS-PAGE as described (6). Membranes were
blotted with antibodies against pERK1/2 (Thr
202/Tyr
204) or total ERK1/2,
pSer
473-PKB or total PKB, hPASK, m/rPASK, or the p85 subunit of PI3K.
Signals were detected using a horseradish peroxidase–labeled anti-rabbit IgG
(BioRad, Richmond, CA) and enhanced chemiluminescence (ECL;
PerkinElmer Las Canada, Woodbridge, ON) on Kodak BioMax XAR ﬁlms
(Kodak, Rochester, NY). The bands were quantiﬁed by G Box Chemi 16 using
Gene Tools from Syngene software (Syngene, Frederick, MD).
Real-time PCR. Total RNA was extracted from aliquots of 100 islets each
using the RNeasy Qiagen micro-kit (Qiagen, Mississauga, ON). MIN6 cell RNA
was extracted by the Trizol method, reverse transcribed, and RT-PCR was
carried out using the Faststart DNA Master PLUS SYBR Green Kit (Roche,
Indianapolis, IN), as previously described (3). All mouse, rat, and human
primer sets, listed in supplementary Table 1 (available in the online appendix
at http://diabetes.diabetesjournals.org/cgi/content/full/db08-0579/DC1), were
designed using Primer3 (20). To amplify preproinsulin pre-mRNA (pre-INS2),
a forward primer was designed against a sequence in exon two and a reverse
primer designed against a sequence in intron 2, as described (21).
Insulin content. Intracellular insulin content was determined by radioimmu-
noassay after acidiﬁed-ethanol extraction.
Statistical analysis. Data are expressed as means  SE and were analyzed
by one-way ANOVA with Bonferroni post hoc adjustment for multiple
comparisons, using GraphPad Instat (GraphPad Software, San Diego, CA);
P  0.05 was considered signiﬁcant.
RESULTS
Palmitate inhibits glucose-induced expression of in-
sulin pre-mRNA and mRNA species in MIN6 cells and
rat islets. The long half-life of mature insulin mRNA
species makes it difﬁcult to examine early changes in
insulin gene expression induced by palmitate (4). To
circumvent this, we used a set of primers against the
short-lived pre-mRNA (pre-INS2), as described by Evans-
Molina et al. (21). We used primers speciﬁc for the insulin
2 gene containing intron 2 because its short half-life
reﬂects earlier changes in transcriptional rates (22). Glu-
cose induced a larger increase in pre-INS2 mRNA than in
mature INS2 mRNA after 24 h of exposure in both MIN6
cells (n  3; P  0.05; Fig. 1A) and rat islets (n  3; P 
0.001; Fig. 1B). Palmitate signiﬁcantly blocked the stimu-
latory effect of glucose on pre-INS2 mRNA within 24 h in
both MIN6 cells (n  3; P  0.001) and rat islets (n  3;
P  0.001), whereas at that time point mature INS2 mRNA
levels were not yet signiﬁcantly decreased (Fig. 1A and B).
Because palmitate inhibition of insulin gene expression is,
at least in part, due to nuclear exclusion of PDX-1 (6), we
measured PDX-1 target genes in islets exposed to glu-
cose  palmitate for 24 h (Fig. 1C). We observed that
during this period glucose induced the expression of
GLUT2 mRNA and islet amyloid polypeptide (IAPP) pre-
mRNA, but not INS1, glucokinase, or IAPP mature mRNA
levels. Palmitate signiﬁcantly decreased INS1 mRNA levels
at both low and high glucose, as well as GLUT2 and
glucokinase mRNA and IAPP pre-mRNA levels at high
glucose (Fig. 1C). To exclude a possible effect of palmitate
on cell viability, we ﬁrst measured caspase 3 cleavage in
MIN6 cells. As expected, a 24-h exposure to IL-1 or
thapsigargin induced caspase 3 cleavage, whereas palmi-
tate had no effect (supplemental Fig. 1). Similarly, culture
of islets for 24 h with palmitate did not lead to an increase
in PI-positive cells, in contrast to the positive control H2O2
(supplemental Fig. 2).
Prolonged exposure of MIN6 cells and isolated rat
islets to high glucose and palmitate increases ERK1/2
and PKB phosphorylation. We ﬁrst assessed the phos-
phorylation state and expression levels of ERK1/2 and PKB in
MIN6 cells and isolated islets. As shown in Fig. 2A–C,
exposure of MIN6 cells to 11 mmol/l glucose time-depen-
dently increased both ERK1 and ERK2 phosphorylation (n 
4; P  0.01; Fig. 2B and C, respectively), which was further
enhanced by addition of palmitate. The effect of palmitate
was detected at 4 h (data not shown), further increased after
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Fig. 2B and C). Ser
473-phosphorylation of PKB was slightly
but not signiﬁcantly enhanced by glucose and strongly aug-
mented by palmitate after 12 h but not 24 h (n  5; P  0.01;
Fig. 2D and E). Similar effects of palmitate on ERK1/2 and
PKB phosphorylation were observed in isolated rat islets
after an 18-h exposure (Fig. 2F and G).
Inhibition of MEK1/2, but not PI3K, partially pre-
vents palmitate inhibition of insulin gene expression.
To determine whether phosphorylation of ERK1/2 and
PKB by palmitate plays a role in the inhibition of insulin
gene expression, pharmacological inhibitors of their re-
spective signaling pathways were used. As expected, glu-
cose-induced ERK1/2 phosphorylation with or without
palmitate was blocked by the MEK1/2 inhibitors U0126
(Fig. 3A) and PD98059 (not shown). PKB phosphorylation
was blocked in the presence of LY294002 (Fig. 3B). In
MIN6 cells, both U0126 and LY294002 signiﬁcantly poten-
tiated the stimulatory effect of glucose on insulin pre-
mRNA (n  4–7; P  0.001; Fig. 3C), suggesting some
degree of tonic inhibition of insulin gene expression by the
ERK1/2 and PKB pathways in MIN6 cells, but not in islets,
in which neither U0126 (Fig. 3D) or LY294002 (Fig. 3F) had
any effect on basal or glucose-stimulated insulin pre-
mRNA expression. Palmitate inhibited insulin pre-mRNA
levels in MIN6 cells at 11 mmol/l glucose (n  4; P  0.001;
Fig. 3C) and rat islets at both 2.8 and 16.7 mmol/l glucose
(n  8; P  0.001; Fig. 3D and E). This effect was partially
reversed in the presence of U0126 in MIN6 cells (Fig. 3C)
and in the presence of either U0126 (Fig. 3D) or PD98059
(Fig. 3E) in rat islets. In contrast, LY294002 did not prevent
palmitate inhibition of insulin pre-mRNA levels in either
MIN6 cells (Fig. 3C) or rat islets (Fig. 3F). Altogether,
these data indicate that blockade of the ERK1/2 pathway,
but not of PKB, partially prevents palmitate inhibition of
insulin gene expression.
C2-ceramide enhances ERK1/2 phosphorylation and
inhibits insulin gene expression in MIN6 cells. We
have previously shown that de novo ceramide synthesis
mediates palmitate inhibition of insulin gene expression in
islets (4). To address whether the effect of ceramide is
mediated by ERK1/2 phosphorylation, we exposed MIN6
cells to the cell-permeable analog C2-ceramide in the
absence or presence of MEK1/2 inhibitors (Fig. 4). First,
we observed that C2-ceramide further enhanced ERK1/2
phosphorylation in response to glucose (Fig. 4A), similar
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palmitate. Mature (mINS2) or pre- (mPre-INS2) preproinsulin mRNA levels were measured by RT-PCR and normalized by -actin mRNA levels. B: Rat
islets were cultured for 24 h with 2.8 or 16.7 mmol/l glucose  0.5 mmol/l palmitate. Mature (rINS2) or pre- (rPre-INS2) preproinsulin RNA levels were
measured by RT-PCR and normalized by cyclophillin mRNA levels. C: Insulin 1, GLUT2, glucokinase, and IAPP mRNA as well as IAPP pre-mRNA levels
were measured by RT-PCR and normalized by cyclophillin mRNA levels. Results are expressed as fold increase of the ratio of gene/-actin or cyclophillin
mRNA over the control value and are means  SE of three replicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not signiﬁcant.
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2050 DIABETES, VOL. 58, SEPTEMBER 2009to the effects of palmitate shown in Fig. 2. As expected,
this was blocked in the presence of U0126 or PD98059
(Fig. 4A). C2-ceramide signiﬁcantly inhibited glucose in-
duction of insulin pre-mRNA levels, and this effect was
totally prevented in the presence of U0126 (Fig. 4B). The
nonmetabolizable analog C2-dihydroceramide had no ef-
fect on insulin gene expression (not shown).
Inhibition of ERK1/2 does not alter the expression
levels of MafA, PDX-1, and C/EBP. We have previously
shown that the molecular mechanisms whereby palmitate in-
hibits insulin gene expression involve decreased MafA expres-
sion and PDX-1 nuclear exclusion (6). On the other hand,
Lawrence et al. (9) have shown that the transcription factor
C/EBP inhibits insulin promoter activity. We examined
whether ERK1/2 was involved in the changes in MafA, PDX-1,
and C/EBP expression in response to palmitate. As expected,
a 24-h exposure of MIN6 cells to elevated glucose increased
MafAandPDX-1mRNAanddecreasedC/EBPmRNA(Fig.5A,
B, and C, respectively). Addition of palmitate decreased MafA
mRNA (Fig. 5A) but did not alter PDX-1 (Fig. 5B) or C/EBP
mRNA (Fig. 5C), and these effects of palmitate were unchanged
in the presence of the MEK1/2 inhibitor U0126.
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gene expression. PASK has been demonstrated to play a
role in metabolic sensing and in the control of insulin gene
expression by glucose in pancreatic -cells (15,23,24). A
6-h exposure to high glucose induced a signiﬁcant increase
in PASK mRNA levels in MIN6 cells (n  3; P  0.05; Fig.
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replicate experiments. **P < 0.01, ***P < 0.001.
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with a previous report (15). The concomitant presence of
palmitate nearly abrogated glucose-induced PASK mRNA
expression in both MIN6 cells (Fig. 6A) and rat islets (Fig.
6B). A similar pattern was observed at the protein level in
MIN6 cells (Fig. 6C and D). To determine whether palmi-
tate inhibition of PASK expression mediates its effects on
the insulin gene, we ﬁrst infected MIN6 cells with an
adenovirus encoding for wild-type hPASK (Fig. 7A). As
previously reported (15), overexpression of hPASK signif-
icantly increased insulin gene expression at low glucose
(P  0.001; Fig. 7B). In MIN6 cells infected with a control
adenovirus expressing luciferase (Luc), palmitate inhib-
ited glucose-induced insulin pre-mRNA levels after 24 h of
exposure (n  7; P  0.05; Fig. 7B). In contrast, palmitate
had no effect on insulin pre-mRNA in MIN6 cells overex-
pressing hPASK (n  7; NS; Fig. 7B). Overexpression of
PASK did not affect ERK1/2 phosphorylation (not shown).
These data suggest that PASK mediates palmitate inhi-
bition of insulin gene expression in MIN6 cells. To conﬁrm
these observations in islets, we overexpressed the wild-
type or a kinase-dead mutant of hPASK in islets using
arterial adenoviral delivery (Fig. 7C). After isolation, islets
were exposed to 16.7 mmol/l glucose and 0.5 mmol/l palmi-
tate. We veriﬁed that the adenoviral infection did not affect
cell viability, as indicated by the absence of propidium
iodide-positive cells (supplemental Fig. 2C–E). In islets ex-
posed to elevated glucose and palmitate, overexpression
of wild-type hPASK increased insulin pre-mRNA levels
(Fig. 7D), consistent with the observation in MIN6 cells
(Fig. 7B). The kinase-dead hPASK mutant was previously
shown to abrogate PASK activity and to block glucose-
induction of insulin promoter activity in MIN6 cells
(15,16). Accordingly, overexpression of the kinase-dead
hPASK mutant in MIN6 cells decreased intracellular insu-
lin content by 28% (1,060  53 vs. 1,484  61 ng/ml in
Luc-expressing cells; P  0.05; n  4). In islets, overex-
pression of kinase-dead hPASK decreased insulin pre-
mRNA and PDX-1 mRNA levels and increased C/EBP
expression (Fig. 7D). To conﬁrm the effects of PASK on
PDX-1 expression, we examined PDX-1 protein levels by
immunohistochemistry (Fig. 8). PDX-1 protein expression
was induced by high glucose (Fig. 8B) and reduced in the
presence of palmitate (Fig. 8C). Wild-type hPASK overex-
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DIABETES, VOL. 58, SEPTEMBER 2009 2053pression enhanced PDX-1 expression at low glucose (Fig.
8D) as well as in the presence of palmitate (Fig. 8F). In
contrast, overexpression of the kinase-dead hPASK mu-
tant blocked the stimulation of PDX-1 expression by
glucose (Fig. 8I).
DISCUSSION
This study aimed to identify the intracellular signaling
pathways mediating palmitate inhibition of insulin gene
expression in pancreatic -cells. We found that palmitate
enhances glucose-induced PKB and ERK1/2 phosphoryla-
tion and decreases glucose-induced PASK expression.
Both ERK1/2 and PASK are implicated in the inhibitory
effects of palmitate on insulin gene expression. Further,
modulation of ERK1/2 phosphorylation seems to occur
downstream of ceramide synthesis, whereas inhibition of
PASK expression decreases PDX-1, but not MafA,
expression.
Our observation that glucose enhances PKB phosphor-
ylation is consistent with a number of previous studies in
pancreatic -cells (12,25–28). This is believed to represent
a protective mechanism by which glucose exerts anti-
apoptotic effects (29). In contrast, the observed effect of
palmitate enhancing PKB phosphorylation in both MIN6
cells and rat islets is in contradiction with most (12,26,30),
but not all (31) previous studies in pancreatic -cells,
C2C12 muscle cells (32), and 3T3-L1 adipocytes (33).
However, most of these studies investigated the proapop-
totic action of fatty acids (12,30,34–36), whereas in our
experimental conditions we did not observe any detect-
able cell death. Therefore, it is possible that under non-
proapoptotic conditions, fatty acids enhance PKB
phosphorylation, whereas when either the concentration
or the length of exposure is increased, fatty acid–induced
cell death is associated with a secondary decrease in PKB
phosphorylation. Martinez et al. (30) demonstrated in
MIN6 cells an early enhancement of PKB phosphorylation
by palmitate at 4 h, followed by a decrease at 24 h
associated with marked cell death. Although the time-
course of changes in PKB phosphorylation is clearly
different in our study in islets than in the Martinez et al.
(30) study in MIN6 cells, their results also suggest that the
effects of palmitate on PKB phosphorylation might be
biphasic.
The observed stimulation of ERK1/2 phosphorylation by
glucose is consistent with several previous studies (8,9,37–
40). As reported (38), PD98059 inhibited glucose-stimula-
tion of insulin mRNA expression. Importantly, both
palmitate and ceramide enhanced ERK1/2 phosphoryla-
tion in MIN6 cells and isolated islets, and blockade of
ERK1/2 phosphorylation by U0126 or PD98059 increased
insulin pre-mRNA expression in the presence of palmitate.
This suggests that the ERK1/2 pathway is implicated in
both the stimulation of insulin gene expression by glucose
and its inhibition by palmitate, consistent with a dual role
of ERK1/2 in the regulation of insulin gene expression by
glucose as reported under glucotoxic conditions (9). Fur-
ther, the inhibitory effect of ceramide on insulin gene
expression was completely reversed upon inhibition of
ERK1/2 in MIN6 cells. In view of our previous ﬁndings that
blockade of de novo ceramide synthesis prevents palmi-
tate inhibition of the insulin gene in islets (4), this obser-
vation suggests that ceramide generated de novo from
palmitate inhibits the insulin gene via ERK1/2 activation.
Because ERK1/2 inhibitors did not affect PDX-1 expres-
sion, we hypothesize that ERK1/2 induces posttransla-
tional modiﬁcations of PDX-1 directly or indirectly,
thereby regulating its nuclear translocation, which we
have shown to be implicated in palmitate inhibition of
insulin gene transcription (3,6).
PASK is an evolutionarily conserved serine/threonine
protein kinase, containing a PAS domain sensitive to the
intracellular environment that regulates the kinase domain
to transduce the signal (41). In budding yeast, it coordi-
nates sugar storage and protein synthesis with carbohy-
drate availability (42). In mammals, it has been
demonstrated to be an important regulator of glycogen
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PASK in vivo remains unclear, because two different
studies using PASK
/ mice exhibited different pheno-
types. Although the ﬁndings of Borter et al. (44) did not
support a role for PASK in the regulation of insulin
expression or secretion, Hao et al. (45) found that
PASK
/ mice had impaired glucose-induced insulin se-
cretion and were protected from high-fat diet–induced
obesity and insulin resistance. In pancreatic -cells, PASK
was shown to be required for glucose-induced insulin gene
transcription (15). In the present study, we demonstrated
that palmitate blocks glucose-induction of PASK expres-
sion, and that overexpression of hPASK prevents the
inhibitory effect of palmitate on insulin mRNA and PDX-1
mRNA and protein expression in MIN6 cells. In addition,
adenoviral-mediated overexpression of wild-type PASK
increased, whereas a kinase-dead mutant of PASK de-
creased, insulin mRNA and PDX-1 protein expression in
islets. The partial restoration of insulin pre-mRNA levels in
islets exposed to glucose and palmitate is presumably
because of a lower transfection efﬁciency than in MIN6
cells, in which restoration was complete.
To better understand the links between the two signal-
ing pathways identiﬁed as implicated in palmitate inhibi-
tion of insulin gene expression (namely ERK1/2 and PASK)
and the transcription factors MafA and PDX-1 that we
previously reported to be involved in this process (3,6), we
measured the expression of these transcription factors
upon ERK1/2 inhibition or PASK overexpression. In addi-
tion, we measured the expression of C/EBP, which was
recently shown to be increased in MIN6 cells exposed to
palmitate (46) and is known to repress insulin gene
transcription (9). First, we observed that expression of
neither MafA nor PDX-1 was augmented in the presence of
U0126 in cells exposed to glucose and palmitate, suggest-
ing that the ERK1/2 pathway does not affect expression of
these transcription factors. This, of course, does not rule
out the possibility that ERK1/2 regulates the activity of
these factors at the posttranslational level (9,47). Second,
expression of PDX-1 was inhibited in islets overexpressing
the kinase-dead hPASK mutant, suggesting that PASK
regulates PDX-1 mRNA expression, as previously shown
by da Silva Xavier et al. (15) under high-glucose condi-
tions. Whether or not this is associated with changes in
PDX-1 binding activity remains to be examined. Contrary
to a recent observation by Plaisance et al. (46), we did not
observe an increase in C/EBP expression in MIN6 cells
exposed to high glucose and palmitate. This difference
might be because of a lower concentration of palmitate
and shorter exposure in our study. Interestingly, overex-
pression of the kinase-dead hPASK mutant resulted in a
marked increase in C/EBP expression, which could con-
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DIABETES, VOL. 58, SEPTEMBER 2009 2055tribute to the decrease in insulin gene expression under
these conditions. We hypothesize that under our relatively
mild conditions of exposure to glucose and palmitate,
which are not associated with cell death, C/EBP expres-
sion is not yet increased, whereas under more drastic
conditions, such as kinase-dead hPASK overexpression or
longer times in culture with palmitate (46) or glucose
(9,48), C/EBP expression is enhanced and contributes to
the decrease in insulin gene expression and eventual
cytotoxicity (46). A similar opposite pattern of expression
for PDX-1 and C/EBP was also found in islets from
animal models of type 2 diabetes (48), suggesting that
perhaps PASK regulates these two transcription factors
and, thereby, insulin gene expression under conditions of
fuel surfeit. As we previously observed (6), the concomi-
tant presence of palmitate in culture blocked glucose-
induction of MafA mRNA expression. However, this effect
was prevented neither by ERK1/2 inhibition nor by hPASK
overexpression, suggesting that it is mediated by another,
yet to be identiﬁed, signaling pathway. We acknowledge
that the inherent caveats of pharmacological tools and the
fact that we have not examined transcription factor bind-
ing activities limit the interpretation of our ﬁndings. How-
ever, our results suggest that palmitate inhibits insulin
gene expression by three distinct signaling arms. First, de
novo ceramide synthesis from palmitate activates ERK1/2,
which in turn might affect, directly or indirectly, transcrip-
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glucose-induced PASK expression, which leads to de-
creased PDX-1 expression and, presumably, binding activ-
ity. Third, palmitate inhibits glucose-induced MafA
expression, via mechanisms that do not appear to involve
ERK1/2 or PASK.
In conclusion, we have demonstrated a role for both the
ERK1/2 and PASK pathways in mediating fatty acid inhi-
bition of glucose-induced insulin gene expression in ro-
dent -cells. These ﬁndings uniquely identify PASK as a
novel mediator of glucolipotoxicity on the insulin gene.
Whether or not similar mechanisms are operative in hu-
man islets remains to be examined.
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